<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A study to evaluate WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels in peripheral blood (PB) and bone marrow aspirate (BM) was conducted in 172 patients, including 115 with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), in Japan </plain></SENT>
<SENT sid="1" pm="."><plain>The level of WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was evaluated according to the French-American-British (FAB) and World Health Organization (WHO) classifications (2001, 2008) and using the International Prognostic Scoring System and the WHO Prognostic Scoring System scales </plain></SENT>
<SENT sid="2" pm="."><plain>WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels in PB and BM were well correlated (r = 0.85), and they tended to increase with disease stage progression and in those at higher risk of leukemic transformation </plain></SENT>
<SENT sid="3" pm="."><plain>WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression can be a useful marker for the diagnosis and risk evaluation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>